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Tolerance to both the bronchoprotective effect, and, to a lesser extent, the bronchodilator
activity, occurs with all inhaled b2-agonists. Assumed the importance of this topic and the
lack of a clinical evaluation specifically designed to assess the impact of chronic administra-
tion of indacaterol on the response to salbutamol, we sought to compare the effect of 4-
week treatment with indacaterol 150 mg once-daily versus formoterol 12 mg twice-daily on
the dose-response curve to inhaled salbutamol (total cumulative dose of 800 mg) in a non-
double-blinded, crossover, randomised, and controlled pilot trial that enrolled 20 outpa-
tients with moderate to severe COPD. At the end of 4-week treatments, there was not a sta-
tistically significant difference between the two trough FEV1 (p Z 0.16), and both
indacaterol and formoterol were able to produce a significant (p < 0.001) increase in FEV1
mean differences (L) Z indacaterol 0.15 (95% confidence interval (CI) 0.12e0.18); formoter-
ol 0.10, (95% CI 0.08e0.12) 2 h after their inhalation. Salbutamol elicited an evident dose-
dependent increase in FEV1 and this occurred also after regular treatment with indacaterol
and formoterol with a further mean maximum increase of 0.10L (95% CI 0.05e0.14) and
0.05L (95% CI 0.02e0.08), respectively. The differences between indacaterol and formoterol
in FEV1 increases after salbutamol were never statistically significant. The results ofrmacologia Clinica Respiratoria, Dipartimento di Medicina dei Sistemi, Universita` di Roma ‘Tor Ver-
, Italy.
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Indacaterol and salbutamol in stable COPD 849this study support the use of salbutamol as rescue medication for rapid relief of broncho-
spasm in patients suffering from COPD, even when they are under regular treatment with
indacaterol.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Tolerance to both the bronchoprotective effect, and, to a
lesser extent, the bronchodilator activity, occurs with all
b2-agonists.
1 Bronchodilator tolerance develops rapidly,
with a reduced response to salbutamol after a single dose
of formoterol and reaches a plateau after 1 week of regular
therapy.2 Apparently, the degree of b2-agonist tolerance
increases with the degree of bronchoconstriction.3
Clinically relevant tolerance to rescue b2-agonist treat-
ment is likely to occur in asthmatic patients treated with
LABAs.4 Tolerance to the bronchodilator effects of LABAs
may occur with their prolonged use also in COPD.5 However
in COPD, a pre-treatment with a conventional dose of for-
moterol or salmeterol does not prevent the possibility of
inducing a further bronchodilation with salbutamol.6
Moreover, the results of another study suggest that during
chronic therapy with conventional doses of formoterol in
moderate-to-severe COPD, the add on use of salbutamol
does not improve peak expiratory flow and FEV1 markedly,
but is still effective in reducing air trapping, as shown by
the increase in FVC and possibly dynamic pulmonary hy-
perinflation in the presence of tidal expiratory flow limi-
tation at rest.7
The lack of induction of tolerance is an occurrence
extremely useful because the usual approach in a COPD
patient who complains of worsening dyspnoea and in which
the physician suspects an increase of bronchial obstruction
is to use salbutamol as rescue medication to produce rapid
relief of bronchospasm.
Nonetheless, there are some differences between LABAs
that could cause difference in airway response to salbuta-
mol. Thus, high-efficacy agonists may cause a greater loss
of receptors,8 and it has also been suggested that relevant
tolerance to rescue salbutamol treatment could be more
likely with b2-agonists that are able of a really long resi-
dency at the b2-adrenoceptor.
9 This is because of pro-
longed, 24-h receptor occupancy and the associated
propensity for agonist-promoted reduction in the number
and coupling efficiency of b2-adrenoceptors on airway
smooth muscle and inflammatory cells, where such re-
ceptors are expressed.9
However, Battram et al.10 evaluated the ability of
indacaterol, which is the first LABA able to induce 24-h
bronchodilation, formoterol and salmeterol to induce
tachyphylaxis in guinea pigs. None of the compounds was
subject to desensitization at any of the doses tested.
Indeed, for indacaterol and formoterol, the inhibitory ef-
fect of each dose after 5-day treatment compared with
that of a single treatment was enhanced and reached sig-
nificance for the indacaterol dose of 0.006 and 0.6 mg/kg
and for the formoterol dose of 0.0006 mg/kg. Such a phe-
nomenon was not observed for salmeterol.Assumed the importance of this topic and the lack of a
clinical evaluation specifically designed to assess the
impact of chronic administration of indacaterol on the
response to salbutamol, we assessed whether a regular
treatment with this once-daily LABA might modify the dose-
response curve to inhaled salbutamol in patients with sta-
ble COPD.
Patients and methods
We studied 20 outpatients with moderate to severe COPD,
They were 60 years of age, current or former smokers
(>10 pack-years), reporting chronic cough with or without
sputum production and/or dyspnoea when walking quietly
on level ground. In addition, all patients had FEV1 70%
of predicted normal, and a best post-bronchodilator
(salbutamol 200 mg) FEV1/FVC of less than 0.7. Table 1
describes the baseline characteristics of the randomised
patients.
Patients had experienced no change in symptom severity
or treatment in the preceding 2 months, had shown no signs
of a respiratory tract infection in the month preceding or
during the trial, and had not taken oral corticosteroids,
other inhaled or oral bronchodilators, leukotriene modifiers
or b2-blockers for at least 2 months. Patients were allowed
to continue taking inhaled corticosteroids, provided a
regimen of regular use had been stable for at least 1 month
previously. Patients with a history of allergic diseases such
as allergic rhinitis, asthma and atopic dermatitis (eczema),
and positive skin test or with a total blood eosinophil count
>400 mm3 were excluded. Patients were also excluded if
they had any coexisting cardiovascular or lung disorder, a
resting PaO2 of less than 60 mm Hg, or use of long-term
oxygen therapy (Fig. 1). Patients were asked to refrain
from consumption of cola drinks, coffee, tea, and from
smoking, in the 12 h before and also during the
investigation.
The study was conducted according to the rules of the
declaration of Helsinki and each patient gave written
informed consent to all procedures.
This was a non-double-blinded, crossover, randomised,
and controlled pilot trial. The total study duration was 10
weeks. It had three parts. Part 1 was the run-in period of 1-
week duration that followed screening visit 1. During this
period, patients received inhaled salbutamol for relief
therapy and they were asked to withhold rescue salbutamol
for 8 h prior to come to our outpatient office for the next
visit at the end of the run-in period when baseline mea-
surements (FEV1 and FVC) were performed, and the eligi-
bility of screened patients to participate in the randomized
treatment periods was assessed. In addition to the quali-
fying spirometric tests, each patient was subjected to the
evaluation of the response of his/her airways to increasing
Table 1 The baseline characteristics of the randomised patients.
Patients Age Gender Race Height
(cm)
Weight
(kg)
BMI FEV1 (%
predicted)
FVC (%
predicted)
Reversibility
(% baseline)
Concomitant
medications
Patients who received first indacaterol followed by formoterol
1 73 M Caucasian 175 90 29 66.6 84.0 12.2
2 63 M Caucasian 162 82 31 69.8 86.3 8.6
3 65 M Caucasian 170 82 28 39.8 60.4 13.7 Budesonide
4 64 M Caucasian 170 58 20 31.1 58.0 7.6 Budesonide
5 65 M Caucasian 170 78 27 40.3 61.2 9.3 Budesonide
6 73 M Caucasian 174 88 29 67.9 83.3 5.2
7 70 M Caucasian 160 75 29 69.5 87.8 8.7
8 76 M Caucasian 161 87 34 30.5 57.1 8.8 Budesonide
9 64 F Caucasian 155 58 24 68.6 88.7 17.6
10 69 M Caucasian 169 82 29 46.8 68.4 12.3 Budesonide
Patients who received first formoterol followed by indacaterol
1 80 M Caucasian 176 85 27 36.8 74.5 17.1 Budesonide
2 72 M Caucasian 175 69 23 43.0 63.8 13.6 Budesonide
3 73 M Caucasian 162 77 29 68.9 91.8 14.8
4 63 M Caucasian 163 84 32 68.4 88.4 9.2
5 70 M Caucasian 169 57 20 32.7 66.8 12.2 Budesonide
6 63 F Caucasian 162 59 22 45.9 81.1 19.6 Budesonide
7 77 M Caucasian 165 75 28 63.3 82.2 9.3
8 68 M Caucasian 175 81 26 42.0 59.5 18.9 Budesonide
9 64 M Caucasian 170 86 30 52.4 71.6 13.3
10 71 M Caucasian 163 81 30 64.2 84.9 15.4
850 M. Cazzola et al.dose of salbutamol. A dose-response curve to inhaled sal-
butamol was constructed 2 h after inhalation of placebo
using a dose of 100, 100, 200 and 400 mg e that is a total
cumulative dose of 800 mg. Dose increments were given at
20 min intervals with measurements being made 15 min
after each dose.Figure 1 Consort diagram showing the flow ofPart 2 and part 3 constituted the randomized treatment
periods. Each period was of 4-weeks’ duration. At the end
of the run-in period, at visit 2, eligible patients were
randomized to one of the two open-label treatment se-
quences: (1) indacaterol 150 mg once-daily in part 2, for-
moterol 12 mg twice-daily in part 3; and (2) formoterolparticipants through each stage of the trial.
Indacaterol and salbutamol in stable COPD 85112 mg twice-daily in part 2, indacaterol 150 mg once-daily
in part 3. At the end of each 4-week treatment, at 24 h
after the last dose of indacaterol or 12 h after the last
dose of formoterol, patients returned to our outpatient
office and underwent spirometry for the assessment of
trough FEV1 and FVC and soon after they inhaled a further
dose of indacaterol or formoterol. Two hours after the
inhalation of each treatment, all patients underwent a
new spirometry, and then a dose-response curve to
inhaled salbutamol was constructed again. There was 1-
week washout period between treatment periods during
which the only medication allowed was salbutamol for
relief therapy and, again, patients were asked to withhold
rescue salbutamol for 8 h prior to come to our outpatient
office for the next visit.
All experiments began at 9 a.m. to avoid well-known
interference of the circadian rhythm on bronchomotor tone.
The maximum FEV1 value during the dose-response
curve to salbutamol was chosen as the primary outcome
variable to compare the two treatments. Analysis of
spirometric data for each treatment was performed using
the Student’s t-test for paired variables. Mean responses
were also compared by multifactorial analysis of variance
(ANOVA) to establish any significant overall effect between
the two treatments. In the presence of a significant overall
ANOVA, Duncan’s multiple range testing with 95% confi-
dence limits was used to identify where differences were
significant. A probability level of p < 0.05 was considered as
being of significance for all tests.Figure 2 Mean dose-response curves to inhaled salbutamol const
week treatments 2 h after inhaling indacaterol, or formoterol, for
followed by formoterol; C, patients who received first formoterolResults
All patients completed the study that lasted 10 weeks.
Baseline FEV1 values were not significantly different
following each of the three treatment periods (p > 0.05).
At the end of 4-week treatments, there was not a sta-
tistically significant difference between the two trough
FEV1 (pZ 0.16), and both indacaterol and formoterol were
able to produce a significant (p < 0.001) increase in FEV1
(mean differences (L) Z indacaterol 0.15, 95% confidence
interval (CI) 0.12e0.18; formoterol 0.10, 95% CI 0.08e0.12)
2 h after their inhalation (Fig. 2A).
Salbutamol induced a further dose-dependent increase
in FEV1 after both indacaterol and formoterol, but the in-
crease after indacaterol was larger than after formoterol,
at least with the two higher cumulative doses of salbutamol
(salbutamol 400 mg: mean difference (L) Z indacaterol
0.07, 95% CI 0.02e0.12; formoterol 0.03, 95% CI
0.007e0.05; and salbutamol 800 mg: mean difference
(L)Z indacaterol 0.10, 95% CI 0.05e0.14; formoterol 0.05,
95% CI 0.02e0.08), although differences between indaca-
terol and formoterol in FEV1 increases after salbutamol
were never statistically significant (p Z 0.083, p Z 0.821,
p Z 0.121 and p Z 0.073, after 100, 200, 400 and 800 mg
cumulative dose, respectively) (Fig. 2A). The FEV1 area
under the salbutamol response curve was lower after for-
moterol (0.18L; 95% CI 0.14e0.23) therapy compared to
indacaterol (0.24L, 95% CI 0.14e0.34), although the dif-
ference was not statistically significant (p Z 0.271).ruction at basal 2 h after inhaling placebo, and at the end of 4-
FEV1. A, all patients; B, patients who received first indacaterol
followed by indacaterol.
852 M. Cazzola et al.In the patients who received first indacaterol followed by
formoterol, the mean increase caused by indacaterol was
0.13L (95% CI 0.08e0.18) and that elicited by formoterol was
0.09L (95% CI0.05e0.14), whereas in the patients who
received first formoterol followed by indacaterol, it was
0.17L (95% CI 0.14e0,20) for indacaterol and 0.11L (95% CI
0.08e0.13) for formoterol, respectively (Fig. 2B and C). In
the first group, the two higher cumulative doses of salbuta-
mol induce a further mean increase in FEV1 (salbutamol
400 mg: mean difference (L) Z indacaterol 0.06, 95% CI
0.01e0.14; formoterol 0.04, 95% CI 0.001e0.08; and salbu-
tamol 800 mg:mean difference (L)Z indacaterol 0.09, 95% CI
0.02e0.16; formoterol 0.05, 95% CI 0.002e0.10) (Fig. 2B).
Also, in the patients who received first formoterol followed
by indacaterol, the two higher cumulative doses of salbuta-
mol induce a further mean increase in FEV1 (salbutamol
400 mg: mean difference (L) Z indacaterol 0.07, 95% CI
0.02e0.15; formoterol 0.02, 95% CI 0.001e0.05; and salbu-
tamol 800 mg:mean difference (L)Z indacaterol 0.11, 95% CI
0.04e0.17; formoterol 0.05, 95% CI 0.003e0.10) (Fig. 2C).
Improvements in FVC closely reflected the FEV1 results
(Fig. 3).
Discussion
This study confirms that in COPD patients formoterol does
not reduce the possibility of inducing a further bronchodi-
lation with salbutamol6 and, for the first time to the best of
our knowledge, it shows that a regular treatment with
indacaterol does not alter bronchodilator response to
repeated doses of this short-acting b2-agonist.
Our findings fit well with the documentation that on
isolated human bronchi pre-contracted with 1 mM carbachol
and at concentrations inducing w20 and 35% inhibition,
formoterol and indacaterol did not affect the potency of
isoprenaline-induced bronchi relaxation.11 Moreover,
tolerance has not been observed with long-term indaca-
terol administration.12e14 The lack of antagonism with
short-acting b2-agonists may have potential clinical con-
notations regarding the use of salbutamol as rescue therapy
in common clinical practice.
Current knowledge does not allow us to establish
whether the lack of tolerance is due to the pharmacologicalFigure 3 Mean dose-response curves to inhaled salbutamol
construction at basal 2 h after inhaling placebo, and at the end
of 4-week treatments 2 h after inhaling indacaterol, or for-
moterol, for FVC.properties of b2-agonists used in this study or the disease
suffered by our patients.
It still remains unclear whether functional tachyphylaxis
is different in those who use different inhaled b-agonists,
be they LABAs such as salmeterol, indacaterol, and for-
moterol, or short-acting b-agonists such as salbutamol.15 In
effect, we still do not know whether the degree of agonist-
induced desensitization of the b2-adrenoceptor is related to
agonist efficacy (strength of signalling).
Charlton8 has suggested that the maximal achievable
response to the partial agonist reduces immediately upon
loss of receptors, but the high-efficacy agonist can tolerate
up to 90% loss of receptor before any effect is observed on
the maximal response to the ligand. Hence, dose escalation
with the high-efficacy agonist will result in a maintained
response, even if 90% receptors are lost from the system.
Increasing the dose of the low-efficacy agonist will not,
however, gain any additional effect. Nevertheless, we must
highlight that salmeterol, which is a low-efficacy agonist,
has in cell-based studies exhibited resistance to agonist-
induced b2-adrenoceptor desensitization, raising the pos-
sibility that the intrinsic activity of an agonist may
influence mechanisms of homologous desensitization.16,17
Conversely, Du¨ringer et al.18 did not find evidence to sup-
port this conclusion. In particular, the reduced respon-
siveness did not correlate with high agonist intrinsic activity
because the high-intrinsic-activity agonists isoprenaline
and formoterol induced the least loss of responsiveness. In
general, the lower-efficacy agonists caused a greater loss of
responsiveness, likely because of the reduced wash out of
the more lipophilic compounds, but there were exceptions
to this pattern.18 In particular, indacaterol induced much
less desensitization than would be expected from its large
degree of retention in the cells.18 Individual agonists may
induce specific receptor conformations to produce unique
signalling patterns,19e21 suggesting the possibility for each
agonist to display a unique effect due to both receptor
antagonism and desensitization.18
In any case, there has been some controversy in the
literature regarding tolerance associated with long-term use
of LABAs in patients with COPD.22,23 Although tolerance to
chronic administration of inhaled b2-agonists has not been
adequately addressed in patients with COPD, there seems to
be much more tolerance to bronchodilators in asthma than
in COPD. It is possible that, due to the different pathogenic
mechanisms involved in bronchoconstriction in COPD
compared to asthma, tolerance to b2-agonists may not occur
or the magnitude of tolerance may be different.22 Tolerance
is more noticeable with bronchoprotection than bronchodi-
lation, perhaps reflecting the smaller number of b2-adre-
noceptors on inflammatory cells vs. the 40,000 b2-
adrenoceptors on human airway smooth-muscle cells.24
In conclusion, the results of this study support the use of
salbutamol as rescue medication for rapid relief of bron-
chospasm in patients suffering from COPD, even if they are
under regular treatment with indacaterol.Conflict of interest statement
We declare that we have no conflict of interest with this
study that has not been sponsored by any Drug Company.
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